{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:18:01Z","timestamp":1778473081639,"version":"3.51.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Heart failure (HF) and acute myocardial infarction (AMI) may contribute to cancer development through shared and disease-related pathophysiological pathways. We investigated the mid-term risk of incident cancer in patients with HF or AMI using a large, real-world dataset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with a first hospitalization for acute HF or AMI between October 2015 and October 2024 were included from the TriNetX Global Collaborative Research Network. Patients with prior or concurrent cancer were excluded. Each cohort was matched 1:1 with controls without HF or AMI using propensity score matching. The primary end-point was any new cancer diagnosis occurring during follow-up, starting 6 months after the index hospitalization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After matching, 120 783 patients with HF and 7896 patients with AMI were included. Over a median follow-up of 13 months in the HF cohort and 16 months in the AMI cohort (after the 6-month landmark), both groups showed an higher incidence of cancer compared with controls (HF: HR 2.80 [95% CI, 2.69; 2.91]; AMI: HR 2.02 [95% CI, 1.71; 2.39]; both P &amp;lt; .001). In both cohorts, the excess risk was more pronounced for haematologic than for solid malignancies (HF: HR: 6.78 vs 2.53; AMI: HR: 4.45 vs 1.77). HF with preserved ejection fraction was associated with a slightly higher cancer incidence than HF with reduced or mildly reduced ejection fraction (HR 1.10 [95% CI, 1.04; 1.17], P = .002), whereas no difference was observed between ST and non-ST segment elevation AMI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this large, real-world cohort, both HF and AMI were associated with an increased incidence of cancer, particularly haematologic malignancies. HF was associated with a greater excess risk than AMI. These findings are hypothesis-generating and warrant further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejhf\/xuag061","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T12:23:22Z","timestamp":1772454202000},"source":"Crossref","is-referenced-by-count":1,"title":["Incident cancer in heart failure, myocardial infarction or both: a report from a global federated research network"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2940-5349","authenticated-orcid":false,"given":"Massimiliano","family":"Camilli","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Sciences-CUORE, Fondazione Policlinico Universitario A. Gemelli IRCCS , Largo Agostino Gemelli 8, 00168, Rome ,","place":["Italy"]},{"name":"Department of Cardiovascular Sciences-CUORE, Catholic University of the Sacred Heart , Largo Francesco Vito 1, 00168, Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[{"name":"CHRU de Nancy, Centre d\u2019Investigation Clinique Plurith\u00e9matique 1433, INSERM, Universit\u00e9 de Lorraine, INSERM U1116\u2014DCAC, and F-CRIN iNI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Ameri","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Genova , Genoa ,","place":["Italy"]},{"name":"Cardiac, Thoracic and Vascular Department, IRCCS Azienda Ospedaliera Metropolitana , Genoa ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Ballacci","sequence":"additional","affiliation":[{"name":"Cardiothoracic Department, University Hospital Santa Maria Della Misericordia , Udine ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Lombardo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences-CUORE, Fondazione Policlinico Universitario A. Gemelli IRCCS , Largo Agostino Gemelli 8, 00168, Rome ,","place":["Italy"]},{"name":"Department of Cardiovascular Sciences-CUORE, Catholic University of the Sacred Heart , Largo Francesco Vito 1, 00168, Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Duarte","sequence":"additional","affiliation":[{"name":"CHRU de Nancy, Centre d\u2019Investigation Clinique Plurith\u00e9matique 1433, INSERM, Universit\u00e9 de Lorraine, INSERM U1116\u2014DCAC, and F-CRIN iNI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9200-2729","authenticated-orcid":false,"given":"Guillaume","family":"Baudry","sequence":"additional","affiliation":[{"name":"CHRU de Nancy, Centre d\u2019Investigation Clinique Plurith\u00e9matique 1433, INSERM, Universit\u00e9 de Lorraine, INSERM U1116\u2014DCAC, and F-CRIN iNI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tripti","family":"Rastogi","sequence":"additional","affiliation":[{"name":"CHRU de Nancy, Centre d\u2019Investigation Clinique Plurith\u00e9matique 1433, INSERM, Universit\u00e9 de Lorraine, INSERM U1116\u2014DCAC, and F-CRIN iNI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9404-8846","authenticated-orcid":false,"given":"Filippo","family":"Crea","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences-CUORE, Catholic University of the Sacred Heart , Largo Francesco Vito 1, 00168, Rome ,","place":["Italy"]},{"name":"Center of Excellence of Cardiovascular Sciences, Ospedale Isola Tiberina\u2014Gemelli Isola , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7732-0887","authenticated-orcid":false,"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institute , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Monzo","sequence":"additional","affiliation":[{"name":"CHRU de Nancy, Centre d\u2019Investigation Clinique Plurith\u00e9matique 1433, INSERM, Universit\u00e9 de Lorraine, INSERM U1116\u2014DCAC, and F-CRIN iNI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,5,10]]},"reference":[{"key":"2026051011463745500_xuag061-B1","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jaccao.2025.04.007","article-title":"Bidirectional interaction in cardio-oncology toward novel therapeutic strategies for cardiovascular diseases: JACC: cardioOncology primer","volume":"7","author":"Awwad","year":"2025","journal-title":"JACC CardioOncol"},{"key":"2026051011463745500_xuag061-B2","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/ejhf.2029","article-title":"Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"22","author":"de Boer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026051011463745500_xuag061-B3","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1161\/CIRCULATIONAHA.118.033603","article-title":"Linking heart failure to cancer: background evidence and research perspectives","volume":"138","author":"Bertero","year":"2018","journal-title":"Circulation"},{"key":"2026051011463745500_xuag061-B4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jaccao.2023.01.010","article-title":"Risk of cancer after diagnosis of cardiovascular disease","volume":"5","author":"Bell","year":"2023","journal-title":"JACC CardioOncol"},{"key":"2026051011463745500_xuag061-B5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jaccao.2021.11.007","article-title":"Cancer incidence and mortality according to Pre-existing heart failure in a community-based cohort","volume":"4","author":"Bertero","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026051011463745500_xuag061-B6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40959-023-00158-1","article-title":"Cancer incidence and mortality in patients diagnosed with heart failure: results from an updated systematic review and meta-analysis","volume":"9","author":"Camilli","year":"2023","journal-title":"Cardiooncology"},{"key":"2026051011463745500_xuag061-B7","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","article-title":"Anthracycline cardiotoxicity in adult cancer patients: JACC: cardioOncology state-of-the-art review","volume":"6","author":"Camilli","year":"2024","journal-title":"JACC CardioOncol"},{"key":"2026051011463745500_xuag061-B8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"key":"2026051011463745500_xuag061-B9","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jaccao.2025.04.007","article-title":"Bidirectional interaction in cardio-oncology toward novel therapeutic strategies for cardiovascular diseases: JACC: cardioOncology primer","volume":"7","author":"Awwad","year":"2025","journal-title":"JACC CardioOncol"},{"key":"2026051011463745500_xuag061-B10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jaccao.2024.10.010","article-title":"Shared mechanisms in cancer and cardiovascular disease: s100A8\/9 and the NLRP3 inflammasome: JACC: cardioOncology state-of-the-art review","volume":"7","author":"Van Linthout","year":"2025","journal-title":"JACC CardioOncol"},{"key":"2026051011463745500_xuag061-B11","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.jaccao.2025.04.003","article-title":"Risk of hematologic malignancies in patients with acute myocardial infarction: a nationwide population-based cohort study","volume":"7","author":"Yoon","year":"2025","journal-title":"JACC CardioOncol"},{"key":"2026051011463745500_xuag061-B12","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.125.044046","article-title":"Comparative mortality in heart failure on guideline-directed medical therapy versus malignant cancer: a report from a global federated research network","volume":"14","author":"Monzo","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"2026051011463745500_xuag061-B13","doi-asserted-by":"publisher","DOI":"10.1111\/eci.70012","article-title":"Apixaban in patients with nonvalvular atrial fibrillation, heart failure and low body weight: a report from a global federated research dataset","volume":"55","author":"Monzo","year":"2025","journal-title":"Eur J Clin Invest"},{"key":"2026051011463745500_xuag061-B14","author":"Ferlay"},{"key":"2026051011463745500_xuag061-B15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026051011463745500_xuag061-B16","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2024.49","article-title":"Cardio-oncology: emerging concepts in cardiovascular sequelae of cancer therapies, translational research and reverse cardio-oncology","volume":"20","author":"Camilli","year":"2025","journal-title":"Eur Cardiol"},{"key":"2026051011463745500_xuag061-B17","doi-asserted-by":"publisher","first-page":"oead073","DOI":"10.1093\/ehjopen\/oead073","article-title":"Association between heart failure and the incidence of cancer: a systematic review and meta-analysis","volume":"3","author":"Jaiswal","year":"2023","journal-title":"Eur Heart J Open"},{"key":"2026051011463745500_xuag061-B18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/eurheartj\/ehad486","article-title":"Inflammation in acute myocardial infarction: the good, the bad and the ugly","volume":"45","author":"Matter","year":"2024","journal-title":"Eur Heart J"},{"key":"2026051011463745500_xuag061-B19","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1001\/jamacardio.2019.0302","article-title":"Connections between clonal hematopoiesis, cardiovascular disease, and cancer: a review","volume":"4","author":"Calvillo-Arg\u00fcelles","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2026051011463745500_xuag061-B20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.7326\/M18-0737","article-title":"Clonal hematopoiesis confers predisposition to both cardiovascular disease and cancer: a newly recognized link between two Major killers","volume":"169","author":"Ebert","year":"2018","journal-title":"Ann Intern Med"},{"key":"2026051011463745500_xuag061-B21","doi-asserted-by":"publisher","first-page":"103964","DOI":"10.1016\/j.ebiom.2022.103964","article-title":"Prevalence and prognostic significance of DNMT3A- and TET2- clonal haematopoiesis-driver mutations in patients presenting with ST-segment elevation myocardial infarction","volume":"78","author":"Wang","year":"2022","journal-title":"EBioMedicine"},{"key":"2026051011463745500_xuag061-B22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1001\/jamacardio.2022.0386","article-title":"TET2-Driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial","volume":"7","author":"Svensson","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026051011463745500_xuag061-B23","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1161\/CIRCULATIONAHA.120.046471","article-title":"Early cardiac remodeling promotes tumor growth and metastasis","volume":"142","author":"Avraham","year":"2020","journal-title":"Circulation"},{"key":"2026051011463745500_xuag061-B24","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1158\/0008-5472.CAN-21-2463","article-title":"Cardiac dysfunction promotes cancer progression via multiple secreted factors","volume":"82","author":"Awwad","year":"2022","journal-title":"Cancer Res"},{"key":"2026051011463745500_xuag061-B25","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1161\/CIRCULATIONAHA.117.030816","article-title":"Heart failure stimulates tumor growth by circulating factors","volume":"138","author":"Meijers","year":"2018","journal-title":"Circulation"},{"key":"2026051011463745500_xuag061-B26","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2026051011463745500_xuag061-B27","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"2026051011463745500_xuag061-B28","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1093\/cvr\/cvac133","article-title":"Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions","volume":"118","author":"Pugliese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026051011463745500_xuag061-B29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026051011463745500_xuag061-B30","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/ejhf.2207","article-title":"The association between heart failure and incident cancer in women: an analysis of the women's health initiative","volume":"23","author":"Leedy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026051011463745500_xuag061-B31","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.pcad.2024.07.002","article-title":"Anthracyclines, diastolic dysfunction and the road to heart failure in cancer survivors: an untold story","volume":"86","author":"Camilli","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"key":"2026051011463745500_xuag061-B32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jaccao.2022.01.099","article-title":"Lifestyle and cardiovascular risk factors associated with heart failure subtypes in postmenopausal breast cancer survivors","volume":"4","author":"Reding","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026051011463745500_xuag061-B33","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1002\/ejhf.70005","article-title":"Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology","volume":"27","author":"Keramida","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026051011463745500_xuag061-B34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.gheart.2018.01.002","article-title":"Survival after MI in a community cohort study: contribution of comorbidities in NSTEMI","volume":"13","author":"Foraker","year":"2018","journal-title":"Glob Heart"},{"key":"2026051011463745500_xuag061-B35","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/eurheartj\/ehac710","article-title":"Cancer is a comorbidity of heart failure","volume":"44","author":"Ameri","year":"2023","journal-title":"Eur Heart J"},{"key":"2026051011463745500_xuag061-B36","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.jacc.2013.04.088","article-title":"Patients with heart failure have an increased risk of incident cancer","volume":"62","author":"Hasin","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026051011463745500_xuag061-B37","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ejhf.472","article-title":"Incidence of cancer in patients with chronic heart failure: a long-term follow-up study","volume":"18","author":"Banke","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026051011463745500_xuag061-B38","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jaccao.2025.07.001","article-title":"Cancer and cardiovascular disease: shared risk factors, mechanisms, and clinical implications: JACC: cardioOncology state-of-the-art review","volume":"7","author":"Alhuneafat","year":"2025","journal-title":"JACC CardioOncol"},{"key":"2026051011463745500_xuag061-B39","doi-asserted-by":"publisher","first-page":"e011980","DOI":"10.1161\/CIRCHEARTFAILURE.124.011980","article-title":"Metabolic effects of the SGLT2 inhibitor dapagliflozin in heart failure across the Spectrum of ejection fraction","volume":"17","author":"Selvaraj","year":"2024","journal-title":"Circ Heart Fail"},{"key":"2026051011463745500_xuag061-B40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00395-024-01059-9","article-title":"Sodium-glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond","volume":"120","author":"Camilli","year":"2025","journal-title":"Basic Res Cardiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag061\/67379779\/xuag061.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag061\/67379779\/xuag061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T15:46:42Z","timestamp":1778428002000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article\/doi\/10.1093\/ejhf\/xuag061\/8526088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,10]]},"references-count":40,"URL":"https:\/\/doi.org\/10.1093\/ejhf\/xuag061","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,10]]},"article-number":"xuag061"}}